Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function.

Ejarque M, Sabadell-Basallote J, Beiroa D, Calvo E, Keiran N, Nuñez-Roa C, Rodríguez MDM, Sabench F, Del Castillo D, Jimenez V, Bosch F, Nogueiras R, Vendrell J, Fernández-Veledo S

British journal of pharmacology19 Nov 2020Cited by 9 (Europe PMC)

PMID32986861DOI10.1111/bph.15278PepBankPUB-32986861

Source link PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In mice, acute central teduglutide decreased food intake.
In plain wordsIn mice, acute teduglutide treatment in the brain reduced food intake.
Peptide
Teduglutide
Outcome
DecreaseFood intake with acute central dosing
Study
mousen: not reported in source
Lean and obese mice
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · centralAs given in this study (mouse).
Source sentences
Summary
Acute but not chronic centrally administered teduglutide decreased food intake and weight-gain.
1 context sentence(design, population, supporting numbers)
Summary · context
Physiological measurements (body weight, food intake, locomotor activity, and energy expenditure) and metabolic studies (glucose and insulin tolerance tests) were performed on lean and obese mice treated with the protease-resistant GLP-2 analogue teduglutide.
Report a problemFND-3298686101
02AnimalAnimal study (in vivo)Efficacy outcome
In mice, acute central teduglutide decreased weight gain.
In plain wordsIn mice, acute teduglutide treatment in the brain reduced weight gain.
Peptide
Teduglutide
Outcome
DecreaseWeight gain with acute central dosing
Study
mousen: not reported in source
Lean and obese mice
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · centralAs given in this study (mouse).
Source sentences
Summary
Acute but not chronic centrally administered teduglutide decreased food intake and weight-gain.
1 context sentence(design, population, supporting numbers)
Summary · context
Physiological measurements (body weight, food intake, locomotor activity, and energy expenditure) and metabolic studies (glucose and insulin tolerance tests) were performed on lean and obese mice treated with the protease-resistant GLP-2 analogue teduglutide.
Report a problemFND-3298686102
03AnimalAnimal study (in vivo)Efficacy outcome
In mice, chronic central teduglutide did not decrease food intake.
In plain wordsIn mice, chronic teduglutide treatment in the brain did not reduce food intake.
Peptide
Teduglutide
Outcome
No significant changeFood intake with chronic central dosing
Study
mousen: not reported in source
Lean and obese mice
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · centralAs given in this study (mouse).
Source sentences
Summary
Acute but not chronic centrally administered teduglutide decreased food intake and weight-gain.
1 context sentence(design, population, supporting numbers)
Summary · context
Physiological measurements (body weight, food intake, locomotor activity, and energy expenditure) and metabolic studies (glucose and insulin tolerance tests) were performed on lean and obese mice treated with the protease-resistant GLP-2 analogue teduglutide.
Report a problemFND-3298686103
04AnimalAnimal study (in vivo)Efficacy outcome
In mice, chronic central teduglutide did not decrease weight gain.
In plain wordsIn mice, chronic teduglutide treatment in the brain did not reduce weight gain.
Peptide
Teduglutide
Outcome
No significant changeWeight gain with chronic central dosing
Study
mousen: not reported in source
Lean and obese mice
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · centralAs given in this study (mouse).
Source sentences
Summary
Acute but not chronic centrally administered teduglutide decreased food intake and weight-gain.
1 context sentence(design, population, supporting numbers)
Summary · context
Physiological measurements (body weight, food intake, locomotor activity, and energy expenditure) and metabolic studies (glucose and insulin tolerance tests) were performed on lean and obese mice treated with the protease-resistant GLP-2 analogue teduglutide.
Report a problemFND-3298686104
05AnimalAnimal study (in vivo)Efficacy outcome
In mice, chronic peripheral teduglutide improved glucose tolerance independently of body weight.
In plain wordsIn mice, chronic peripheral teduglutide improved glucose tolerance independently of body weight.
Peptide
Teduglutide
Outcome
IncreaseGlucose tolerance
Study
mousen: not reported in source
Lean and obese mice
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · peripheralAs given in this study (mouse).
Source sentences
Summary
By contrast, chronic activation of peripheral GLP-2 receptors increased body weight-independent glucose tolerance and had anti-inflammatory effects on visceral adipose tissue.
1 context sentence(design, population, supporting numbers)
Summary · context
Physiological measurements (body weight, food intake, locomotor activity, and energy expenditure) and metabolic studies (glucose and insulin tolerance tests) were performed on lean and obese mice treated with the protease-resistant GLP-2 analogue teduglutide.
Report a problemFND-3298686105
06AnimalAnimal study (in vivo)Efficacy outcome
In mice, chronic peripheral teduglutide had anti-inflammatory effects on visceral adipose tissue.
In plain wordsIn mice, chronic peripheral teduglutide reduced inflammation in visceral fat.
Peptide
Teduglutide
Outcome
DecreaseVisceral adipose inflammation
Study
mousen: not reported in source
Lean and obese mice
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · peripheralAs given in this study (mouse).
Source sentences
Summary
By contrast, chronic activation of peripheral GLP-2 receptors increased body weight-independent glucose tolerance and had anti-inflammatory effects on visceral adipose tissue.
1 context sentence(design, population, supporting numbers)
Summary · context
Physiological measurements (body weight, food intake, locomotor activity, and energy expenditure) and metabolic studies (glucose and insulin tolerance tests) were performed on lean and obese mice treated with the protease-resistant GLP-2 analogue teduglutide.
Report a problemFND-3298686106
07LabIn vitro (cells)Mechanism
In human adipocytes, teduglutide regulated the inflammatory state; the abstract does not state its direction.
In plain wordsIn cells, teduglutide regulated inflammation in human fat cells; the direction was not reported.
Peptide
Teduglutide
Outcome
Direction not reportedAdipocyte inflammatory state
Study
humann: not reported in source
Human adipocytes
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
Finally, teduglutide regulates the inflammatory state and acts as an anabolic signal in human adipocytes.
Report a problemFND-3298686107
08LabIn vitro (cells)Mechanism
In human adipocytes, teduglutide acted as an anabolic signal.
In plain wordsIn cells, teduglutide acted as a growth-promoting signal in human fat cells.
Peptide
Teduglutide
Outcome
IncreaseAnabolic signaling
Study
humann: not reported in source
Human adipocytes
Outcome group
Receptor activity and mechanism · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Finally, teduglutide regulates the inflammatory state and acts as an anabolic signal in human adipocytes.
Report a problemFND-3298686108

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.